Resisting Clinical Translation from Bench to Bedside: The China Case of Liver Cancer Therapeutic Revolution.

It is traditionally believed that liver cancer therapies are undergoing a shift from chemotherapy to targeted therapy, and then to immunotherapy. Nonetheless, in the case of China, targeted therapy for liver cancer still holds a significantly lower share, not to mention the newly launched immunotherapy. In developing countries, policy intervention and financial considerations have resisted the clinical translation from laboratory's bench-side to patients' bedsides.